Mingji Biopharmaceutical

Mingji Biopharmaceutical is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative cell therapies and antibody-based drugs. The company focuses on chimeric antigen receptor T-cell (CAR-T) therapies for both hematological malignancies and solid tumors, utilizing its proprietary M-CAR technology platform to enhance safety and efficacy. Its lead programs include CD19-targeted CAR-T for lymphomas and BCMA-targeted therapies for multiple myeloma. Mingji is also expanding its pipeline into solid tumor indications, targeting antigens such as Claudin-18.2 and Mesothelin. The company aims to provide next-generation immunotherapy solutions through integrated R&D and manufacturing capabilities.